title: Management of hepatitis C patients with decompensated liver disease.
abstract: Little is known about the tolerance and effectiveness of novel oral direct acting antivirals (DAA) in hepatitis C patients with decompensated cirrhosis. To examine the studies relevant to the treatment of hepatitis C virus(HCV)-related decompensated liver disease, we performed computer-based searches for English articles between 1947 and August 2015. Fourteen articles including HCV patients with decompensated cirrhosis were reviewed. The combinations of ledipasvir(LDV)/sofosbuvir(SOF)/ribavirin(RBV) for 12 weeks, or daclatasvir/SOF/RBV for 12 weeks are safe and effective for HCV genotype 1 or 4 infection, and daclatasvir/SOF/RBV for 12 weeks or SOF/RBV for 24 weeks might be effective and safe for HCV genotype 2 or 3 infection. In conclusion, current evidence supports the use of all oral DAA regimens in HCV patients with decompensated cirrhosis.
authors.affiliation: a Division of Gastroenterology, Department of Internal Medicine , Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Taipei , Taiwan.|b School of Post-Baccalaureate Chinese Medicine , Tzu Chi University , Hualien , Taiwan.|c School of Medicine , Tzu Chi University , Hualien , Taiwan.
authors.forename: Ching-Sheng
authors.initials: CS
authors.lastname: Hsu
authors.affiliation: d Graduate Institute of Clinical Medicine , National Taiwan University College of Medicine , Taipei , Taiwan.|e Department of Internal Medicine , National Taiwan University Hospital , Taipei , Taiwan.|f Department of Medical Research , National Taiwan University Hospital , Taipei , Taiwan.|g Hepatitis Research Center , National Taiwan University Hospital , Taipei , Taiwan.
authors.forename: Jia-Horng
authors.initials: JH
authors.lastname: Kao
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000601:surgery / Q000821:virology*; D016031:Liver Transplantation; D018579:Patient Selection; D012008:Recurrence; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents
keywords: Antiviral agents; Direct acting antivirals; Genotype; Hepatitis C; Human; Liver failure